The JAK2 inhibitor baricitinib (Olumiant, from Eli Lilly) was FDA-approved in June 2018 for the treatment of moderately to severely active rheumatoid arthritis (RA). The gene discussed is JAK2; the disease is rheumatoid arthritis.